1Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol, 2007, 5: 890-897.
2Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med, 2007, 357: 2576- 2588.
3DiBisceglie A, Lai CL, Gane E, et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology, 2006, 44(Suppl 1):230A.
5Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology, 2008, 47: 447-454.
6Zeuzem S, Buff M, Gane El, et al. Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis B (the GLOBE study). Hepatology, 2007, 46(Suppl 1): 681A.
7Reddy KR, Rustgi V, Zeuzem S, et al. Week 24 is the optimal time point for predicting outcomes at 2 years with telbivudine. Global Antiviral J, 2007, 121(Suppl 2): 13.
8Standring DN, Patty A, Chapron C, et al. Resistance determination in patients experiencing virologic breakthrough following telbivudine or lamivudine therapy in the international GLOBE trial. Gastroenterology, 2007, 132: 766A.
9Gane E, Lai CL, Min A, et al. Adefovir salvage therapy for virologic breakthrough in Telbivudine-treated patients from the GLOBE study. J Hepatol, 2007, 46 (Suppl 1): S187.
2Lok AS, McMahon B J; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology, 2004, 39: 857-861.
3Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol, 2003, 18: 239-245.
4Mangi A, Villani MR, Minerva N, et al. Efficacy of 5MU of interferon in combination with ribavirin for naive patients with chronic hepatitis C virus: a randomized controlled trial. J Hepatol, 2001,34: 441-446.
5Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology, 2003,37: 600-609.
6Strader DB, Waright T, Thomas DL, et al. Diagnosis, management,and treatment of hepatitis C. Hepatology, 2004, 39: 1147-1171.
7Gauthier J, Bourne EJ, Lutz MW, et al. Quantitation of hepatitis Bviremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis, 1999, 180: 1757-1762.
8Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology, 2001, 34: 785-791.
9Jang JW, Bae SH, Chio JY, et al. Early virological response predicts outcome during extended lamivudine retreatment in patients with chronic hepatitis B who relapsed after initial HBeAg response. J Gastroenterol Hepatol, 2006, 21: 384-391.
